Oral administration of clinical-type high molecular weight urokinase (HMW-UK) in a single dose of 30,000-60,000 International Units (IU) 
Introduction
Urokinase (UK)' is currently being used clinically as a thrombolytic agent in patients with various thromboembolic diseases (1) . This therapeutic plasminogen activator has always been infused intravenously in human subjects. We have been studying the oral administration of high molecular weight urinary urokinase (HMW-UK) in a dog model and in normal human subjects, and have reported that orally administered HMW-UK was absorbed through the intestinal tract in an experimental dog model and in human subjects (2) (3) (4) (5) , producing a plasma fibrinolytic state. A plasma fibrinolytic state was developed, as defined by an increase in urokinase amidolytic activity with a specific synthetic substrate, a decreased euglobulin lysis time, and an increase in plasmin activity, in a large series of volunteer normal human subjects after oral administration of either 30,000 or 60,000 International Units (IU) of clinicaltype HMW-UK. After oral administration of 120,000 IU of pure HMW-UK for either 1 d or daily for 7 d, and oral administration of a placebo daily for 7 d, a new 53,000-mol wt urokinase (UK)-type protein was isolated from plasma samples, from blood drawn 6 h after administration of the capsules. A sequential two-step affinity chromatography method, followed by preparative sodium dodecyl sulfate (SDS)-polyacrylamide electrophoresis, was used to isolate the UK-type protein. The protein was characterized by functional, SDSpolyacrylamide gel electrophoretic, and immunological methods. 1 . Abbreviations used in this paper: ACH-Sepharose, (Na-[e-aminocaproyll-DL-homoarginine hexylester)-Sepharose; ELT, euglobulin lysis time; FDP, fibrinogen/fibrin split products; Glu-Plg, Glu-plasminogen; H-D-Val-Leu-Lys-pNA, H-D-valyl-L-leucyl-L-lysine-p-nitroanilide; HMW-UK, high molecular weight urokinase; IAEF, immunoadsorbent adsorbed-eluted fraction; LMW-UK, low molecular weight urokinase; NPGB, p-nitrophenyl-p'-guanidinobenzoate; pyro-Glu-Gly-Arg-pNA, L-pyroglutamyl-glycyl-L-arginine-p-nitroanilide; UK, urokinase.
Methods
Reagents. Benzamidine HCl (Aldrich Chem. Co., Milwaukee, WI), Trasylol (Bayer Pharmaceutical Co., Ltd., Federal Republic of Germany), Pyro-Glu-Gly-Arg-pNA (S-2444; Kabi Diagnostica, Sweden) and H-D-Val-Leu-Lys-pNA (S-2251; Kabi Diagnostica), Sepharose 4B (Pharmacia Fine Chemicals, Piscataway, NJ), bovine thrombin, 90% pure (Mochida Pharmaceutical Co., Japan), bovine plasminogen-rich fibrinogen (Povite Products, Nakarii Chemicals, Japan), Agarose-L (Behringwerke, Federal Republic of Germany), and plasminogen-free bovine fibrin plates (Daiichi Pure Chemical Co., Japan) were purchased. Human Glu-plasminogen used in the kinetic studies and for plasminogen activator assays was prepared by methods previously described (6) .
[Na(e-aminocaproyl)-DL-homoarginine hexylester]-Sepharose (ACHSepharose) was prepared by methods previously described (7) .
UK preparations. Enteric-coated gelatin capsules were prepared containing either clinical-type human urinary UK powder, with a specific activity of 40,000 IU/mg protein (15,000 IU, 30,000 IU, or 60,000 IU per capsule), or pure HMW-UK powder, with a specific activity of 110,000 IU/mg protein (30,000 IU per capsule). The intravenous preparations (30,000 IU) were clinical-type human urinary HMW-UK. The pure HMW-UK was prepared by a previously described affinity chromatography method with ACH-Sepharose, from partially purified urinary HMW-UK (7) . It had a molecular weight of 53,000, with 92.8% active sites by p-nitrophenyl-p'-guanidinobenzoate (NPGB) titration (8) . It was similar to the highest purity urinary HMW-UK preparation previously used for kinetic studies (6, 9) , and was used as the HMW-UK standard in these studies. For the immunodiffusion studies, pure urinary LMW-UK, prepared from partially purified urinary LMW-UK by the ACH-Sepharose method, was used. It had a molecular weight of 33,000, a specific activity of 230,000 IU/mg protein, and 91.2% active sites.
The enteric-coated gelatin capsule contained, in addition to the HMW-UK powder, 6 mg sodium chloride (Wako Pure Chemical Industries, Ltd., Japan), 24 2, 4, 6, 8, 10 , and 24 h in the oral group, and at 0.5, 1, 2, 4, and 6 h in the intravenous group. 30 additional human subjects were separated into three groups. 10 human subjects were each given four placebo capsules, without UK, in a single dose, daily for 7 d (placebo group). 10 human subjects were each given four capsules containing 30 ,000 IU of pure HMW-UK per capsule in a single dose (1-d group) , and 10 human subjects were each given the same four HMW-UK capsules daily, in a single dose, for 7 d (7-dgroup). Plasma fibrinolytic parameters were measured in these three groups at 0.5, 2, 4, 6, 8, 10 , and 24 h after oral administration of the capsules. In the 7-d group, plasma fibrinolytic parameters were measured only on the seventh day. Blood samples were collected from each individual 6 h after administration of the final dose; in the three groups given pure HMW-UK, the plasmas of each group were pooled and used for the isolation of the HMW-UK-type proteins. Immediately after separation of the plasma samples, 20 KIU of Trasylol per milliliter plasma and 25 mM benzamidine* HCl/ml plasma were added.
Determination offibrinolytic system components in plasma. UKspecific amidolytic activity was determined in the plasma samples and fractions by a modification of the end-point method described by Claeson et al. (10) , with pyro-Glu-Gly-Arg-pNA, measuring released p-nitroaniline (pNA). The system contained 700 ul 100 mM Tris-HCl buffer, pH 8.8, 10 KIU Trasylol, 200 ul plasma, or fraction, and 100
Ml 3 mM S-2444. After incubation for 10 min at 370C, 100 ,l of 50% acetic acid was added to stop the reaction; the absorbance was read at 405 nm. This substrate is useful for determining UK activity, since it is 40-fold more sensitive to UK than to both plasma plasmin and kallikrein, and 10-fold more sensitive to urokinase than to both thrombin and Factor Xa. It can also be used to measure tissue plasminogen activator. Standard curves can be prepared with either pNA or UK (0-40 IU); 1.00 nmol of pNA is equivalent to 1.15 IU UK activity. The data are presented as nanomoles of pNA liberated per milliliter indicating the possibility that non-UK amidolytic activity is included in the measurement. Plasmin (protease) activity in plasma was measured with a plasminogen-free bovine fibrin plate. 20 M1 of plasma was placed on the plate, which was incubated at 37°C for 16 h, and the lysis area, millimeters squared, was calculated. Plasmin (protease) activity is expressed in casein units per deciliter plasma; the casein unit is equivalent to 0.7 IU of plasmin using a standard curve with a reference human plasmin preparation (IRP 77/588) (0-1 X 10-3 casein units). This assay with the fibrin substrate will reflect the protease activity of free plasmin only. Human Glu-Plg activator activity of fractions isolated from plasma was determined with H-D-Val-LeuLys-pNA by an end-point method modification of an initial rate method with highly purified human Glu-plasminogen (6, 9) . The system contained 825 ,l 50 mM Tris-HCl buffer per 100 mM NaCl, pH 7.4, 100 Ml 0.1% gelatin, 5 Ail Glu-plasminogen (1.5 casein units), 0-10 ,l activator, incubated for 2 min at 37°C, followed by 75 Ml S-2251, and incubated for 5 min at 37°C; 100 Ml of 50% acetic acid was added and the absorbance was read at 405 nm. A UK standard curve was prepared (0-4 IU). Protein concentration of fractions isolated from plasma was determined by absorbance measurements at 280 nm using a specific absorbance of EI'm = 13.6, which is the El'm of HMW-UK.
ELT was determined by the method of Milstone (11) with a clot lysis time recorder (Riko Shoji Co., Japan); the euglobulin fraction was precipitated from 0.5 ml plasma, removed by centrifugation, dissolved in 0.5 ml of 20 mM veronal buffer, pH 7.4, and immediately clotted with 0.1 ml bovine thrombin solution (25 U). FDP were measured in serum by a latex agglutination method (12) with a FDPLkit (Teikoku Hormone Mfg. Co., Ltd., Japan). Plasminogen, and two types of antiplasmin, immediate and slow, were determined by an affinity chromatography method with L-lysine-substituted-Sepharose by a method previously described (13). In this method, the plasminogen was removed from the plasma sample by passing it through L-lysineSepharose; the plasminogen was eluted with 100 mM acetic acid, converted to plasmin with streptokinase, and assayed on a casein substrate. The unadsorbed plasma components were assayed for antiplasmin activity by adding excess standard plasmin, incubating at both 0.5 min and at 30 min, and assaying for residual plasmin on a casein substrate.
Immunological studies. Rabbit antibody to HMW-UK was prepared by immunizing rabbits by both foot pad and intradermal injections with 0. (14) . 1 mg of the IgG antibody fraction neutralized almost completely 80 IU of the parent highly purified urinary HMW-UK when the fibrinolytic activity of the IgG antibody-UK mixture was measured by a standard fibrin plate method according to the method of Day et al. (15) . The specific rabbit anti-HMW-UK-IgG-Sepharose was prepared from 20 ml of Sepharose 4B activated by treatment with cyanogen bromide as described by Cuatrecasas (16) , and coupled with 20 mg of rabbit anti-HMW-UKP IgG (100% immobilized) in 100 mM borate buffer containing 50 mM CaCI2, pH 9.3. The Sepharose slurry was washed first with 200 mM Na2CO3 containing 500 mM NaCl followed by 100 mM borate buffer, pH 9.0, containing 500 mM NaCl.
Double immunodiffusion analysis (Ouchterlony method) (17) was carried out at room temperature for 24 h in 1.0%/6 agarose (Behringwerke, Federal Republic of Germany) in a pH 8.6 veronal buffer, ionic strength of 0.05, containing 0.05% NaN3.
Plasminogen activation kinetics. Glu-Plg activation kinetics were carried out and calculated in the same manner as was previously described (6, 9) where K,.4 is the apparent Michaelis constant of activation for the plasminogen substrate, and kpjg is the catalytic rate constant of activation.
Electrophoretic procedures and zymography. SDS-PAGE was carried out in the Ortec acrylamide gel system by methods previously described (18) . Gel slabs (6%) were prepared in 0.1 M phosphate, 0.1% SDS, 0.002 M EDTA buffer, pH 7.0, and electrophoresis was carried out at 320 V and 120 mA for 180 min. Samples for analysis were dissolved in 8 M urea, 0.1% SDS at a concentration of 1-3.5 mg of protein/ml and 10 ul was placed in each slot. The gel slabs were stained with Coomassie Brilliant Blue R250 for 30 min at 65°C and destained. Gels were scanned, after drying, with a Beckman Model 1 10 microzone scanner, both to identify and to quantitate each of the components of samples. Plasminogen activator activity of the protein bands separated on the gel of SDS-PAGE was determined by the zymographic technique of Tissot et al. (19) ; after SDS-PAGE, the gel was washed for 30 min in 2.5% Triton X-100 to remove SDS, placed on plasminogen-rich fibrin-agar plate and incubated at 37°C for 18 h. The plasminogenrich fibrin-agar plate was prepared as follows: 10 ml of fibrinogen (0.8%) in 100 mM phosphate buffer, pH 7.4, was mixed on 13.5 X 9.5-cm plastic plates with 2.5 ml of 20% Triton X-100 in 0.1 M phosphate buffer, pH 7.4, 7.5 ml of 2% agarose in a 0. buffer, pH 7.4, and 0.05 ml of thrombin (100 NIH U/ml) in 0.1 M phosphate buffer, pH 7.4 (the latter two solutions were kept at 540C).
Results
Elevation of plasma fibrinolytic system parameters after oral administration of varying doses of UK in normal human subjects. This study was designed to establish a minimum oral UK dose which would develop a plasma fibrinolytic state in the human subject. Three single consecutive oral doses, 15,000 IU, 30,000 IU, and 60,000 IU, of clinical-type HMW-UK were administered to each subject at l-wk intervals. The three fibrinolytic parameters that showed significant elevation were UK-specific amidolytic activity, plasmin (protease) activity and ELT. UK-specific amidolytic activity was elevated between 2 and 6 h ( Fig. 1) . However, plasmin (protease) activity increased after 6 h, and was elevated between 8 and 12 h (Fig. 2) , showing continuous activation of plasminogen to plasmin by the continuous presence of a plasminogen activator for at least 12 h. The ELT was shortened between 4 and 12 h ( Fig. 3 ), also indicating prolonged fibrinolytic activity (both plasminogen activator and plasmin activities). Each subject was his/her internal control, receiving the increasing doses, consecutively, at weekly intervals. A single intravenous dose of 30,000 IU given as a bolus was used in another group of subjects for comparative purposes. During the first hour after administration, the intravenous dose also showed significant elevation of UK-specific amidolytic activity, and plasmin (protease) generation (Figs. 1 and 2), and also a shortening of the ELT (Fig. 3) .
In both the oral and intravenous groups, some elevation in the FDP was found with the 30,000 IU and 60,000 IU doses but they were not significant. Also, very little change occurred in both the plasminogen and antiplasmin levels at both the three oral doses used and the intravenous dose. The activated partial thromboplastin times, the recalcification times, and thrombin times, using standard methods (2), were all within normal ranges.
. -----T Figure 1 A sequential two-step affinity chromatography method was developed for isolating UK-type proteins from plasma samples. The first step utilizes an ACH-Sepharose column, which permits us to isolate plasma serine proteases, including tissue plasminogen activator and UK-type proteins, perhaps both active and inactive; DFP-inactivated UK is also adsorbed to this affinity column. The second step utilizes a specific rabbit anti-HMW-UK-IgG-Sepharose column, which permits us to isolate the specific UK-type proteins.
Step 1: affinity chromatography with ACH-Sepharose. 20 ml of each plasma sample (pool) containing 400 KIU of Trasylol and 25 mM benzamidine. HCO was passed through an ACH-Sepharose column (wet volume of gel occupies 2.0 X 5.0 cm) equilibrated with 100 mM phosphate buffer, pH 7.4. After washing with 20-30 vol of 100 mM phosphate buffer, pH 7.4, containing 2,000 mM NaCl until the absorbance at 280 nm was zero, the column was eluted with 50 ml of the *1 Figure 3 . Plasma ELT. No Glu-plasminogen activator activity was found in the 7-d placebo plasma fraction. All of the amidolytic activity found in the 7-d placebo plasma sample was adsorbed to the ACHSepharose column, and -80% of the amidolytic activity of the orally administered HMW-UK plasma samples were adsorbed to the column, showing the high specificity of the column for plasma serine proteases. There was no Glu-plasminogen activator activity found in the original plasma samples due to the complexing of transported urokinase with either a transport protein or an inhibitor.
Step 2: immunoadsorbent chromatography with specific rabbit anti-HMW-UK-IgG-Sepharose. The affinity adsorbedeluted fractions, from each of the three 20-ml plasma samples, were each passed through a specific rabbit anti-HMW-UKIgG-Sepharose 4B column (2.0 X 5.0 cm) equilibrated with 0.1 M Tris-phosphate buffer at pH 8.0. The column was washed with 100 ml of the same buffer containing 2 M NaCl, 0.1 M benzamidine* HCl, and 1% Triton X-100, and then 100 ml of the same buffer containing no Triton X-100. Elution of the UK-type proteins was achieved with 50 ml of the same buffer containing 2 M NaCl and 8 M urea, without benzamidine -HCI, and 4-ml fractions were collected. UK-specific amidolytic activity was found in both the unadsorbed fraction, and, the adsorbed-eluted fraction from the orally administered HMW-UK plasma samples. The adsorbed-eluted fraction from the anti-HMW-UK-IgG-Sepharose 4B column was pooled, dialyzed against PBS containing 25 (Table I) .
On the other hand, as shown in Fig. 4 30 ,g of IAEF were applied to 12 gel slots. After electrophoresis, the gels were sliced at the position of 53,000 mol wt, and the slices were extracted with 5 ml of 0.1 M phosphate buffer pH 7.4 containing 0.2% Triton X-100 overnight at 4VC. The supernatant, after glass-wool filtration, was dialyzed against 0.1 M phosphate buffer at pH 7.4 overnight at 4VC and concentrated against Carbowax 20,000. By this preparative SDS-PAGE procedure, 0.29 mg of protein with 360 IU of Glu-Plg activator activity was recovered from 0.79 mg of the fraction containing 4 -425 IU of Glu-Plg activator activity, with a specific activity of 1,241 IU/mg protein, and a recovery of 85%. Since the specific activity of the pure HMW-UK standard is 110,000 IU/mg protein, the active 53,000 mol wt UK-type protein, after preparative SDS-PAGE, is -1% of the total protein, indicating that -99% of the 53,000 mol wt UK-type protein may be in an inactive form, or the protein is a UK-zymogen with a low specific activity. All of the purified 53,000 mol wt UK-type protein, after preparative SDS-PAGE could be bound to specific rabbit anti-HMW-UK-IgG-Sepharose.
The 7-d IAEF SDS-PAGE fraction, containing the 53,000 mol wt protein, formed a precipitin band with the specific rabbit IgG antibody to HMW-UK in double immunodiffusion (Fig. 5) . These results show that the purified 53,000 mol wt UK-type protein has common antigenic determinants with urinary HMW-UK, and also with LMW-UK.
Peptide chain analysis of the plasma 53,000 mol wt UKtype protein. The purified 53,000 mol wt UK-type protein was reduced in 0.1 M phosphate buffer, pH 7.4, containing 1% 2-mercaptoethanol, at 37°C for 30 min. As shown in Fig. 6 A, after reduction, the 53,000 mol wt protein band as well as the highly purified HMW-UK standard separated into two chains that have the same mol wts of 33,000 and 20,000, respectively. The UK-type heavy chains of 33,000 mol wt did not have any plasminogen activator activity on the zymogram after reduction (Fig. 6 B) .
Isolation and characterization of plasminogen from the plasma ofpatients given pure HMW-UK orally. Plasminogen was isolated from the patients' plasma samples, from the 74d placebo, I-d, and 7-d groups, after removal of the UK-type proteins by ACH-Sepharose affinity chromatography. The remaining unadsorbed plasma was subjected to a continuous three-step sequential affinity chromatography method using Zn-chelated-Sepharose (21) (step 1) to remove serine proteases and possible tissue-type plasminogen activators, followed by ACH-Sepharose (step 2) to remove any residual UK-type Glu-form(s), 67% Lys-form(s), and 6% of a plasmin-plasmin inhibitor complex. In order to determine if there was any free plasmin in the preparations, the fractions were completely reduced and alkylated and analyzed by SDS-PAGE (Fig. 7) .
No plasmin heavy (A) and light (B) chains were found in the 7-d placebo group fraction. In the 1-d group fraction, a trace of plasmin was found but in the 7-d group fraction, -9% plasmin was found, calculated from the heavy chain fraction. Therefore, the Lys-form(s) of plasminogen found in the 7-d group fraction was primarily the zymogen(s), with some contaminating plasmin.
Discussion
In these studies, we have shown that the oral administration of urinary HMW-UK in a group of normal human subjects induced a plasma fibrinolytic state (Figs. 1-3 can be converted to an active two-chain enzyme by plasmin. Wun et al. (26) also suggested that the major fractions of the urokinase zymogen isolated by immunoadsorbent affinity column chromatography from enriched plasma fractions may exist in a conformation that is predisposed to degradation rather than to activation by plasmin treatment. Neither the UK-specific amidolytic nor Glu-plg activator activities of the 53,000 mol wt UK-type protein isolated in this study could be enhanced by plasmin treatment.
In these studies on the isolation of UK-type proteins from the plasma of human subjects given urinary HMW-UK orally, we have found that when using the sequential two-step affinity chromatography method followed by the preparative SDS-PAGE method, large amounts of the 53,000 mol wt UK-type protein (0.29 mg/dl plasma) can be isolated from the plasma of the 7-d group, compared to the small amounts isolated from the plasma of the l-d group (<0.03 mg/dl plasma). This indicates that each of the human subjects in the 7-d group contain a total amount of -7.0 mg of UK-type protein in whole blood, assuming a plasma volume of 2,400 ml/60 kg individual. Each individual in the 7-d group was given a total amount of 7 (two-chain) originated in the orally administered HMW-UK, >92% of the HMW-UK was transported and appeared in the blood. This speculation is obviously illogical, because it is well known that the absorption rate of macromolecules across the intestinal tract of human subjects is at most <10% of the total protein administered (27). We reported that in a dog model (5), a single duodenally-administered 1251I HMW-UK dose was transported and appeared in the plasma in <45 min. Also, the biological half-life of UK was found to be <20 min (28) .
We believe that orally administered HMW-UK stimulates the UK biosynthetic pathway, in perhaps the liver (29) and/or vascular endothelium (30) , releasing a single chain UK-type protein, a zymogen form. The UK-zymogen is converted to a two-chain active UK form by plasmin, and any other factors, generated in plasma (see Fig. 2 ). After inducing the plasma fibrinolytic state, active UK is bound to a specific UK inhibitor(s), and eliminated from the blood as the enzyme-enzyme inhibitor complex. This process is probably the reason why the oral administration of HMW-UK can maintain a plasma fibrinolytic state for much longer intervals after administration than the intravenous administration of HMW-UK. We also would like to propose the possibility that the cumulative effect of the oral administration of HMW-UK may be expected even during fibrinolytic therapy, because the Glu-plg activator activity in the IAEF of the 7-d group was two times higher than that of the l-d group, and a large amount of the 53,000 mol wt plasma UK-type protein could be isolated only from the 7-d group.
The 53,000 mol wt protein was isolated from plasma containing the protein, in probably UK-UK inhibitor complexes. A rapid specific inhibitor to both tissue plasminogen activator and UK, which forms possible stoichiometric complexes, has been recently reported (31, 32) . During the fractionation of plasma samples containing these inactive UK-UK inhibitor complexes, they are first adsorbed to ACH-Sepharose and eluted with buffers containing 8 M urea, followed by adsorption to specific rabbit anti-HMW-UK-IgG-Sepharose and eluted with 8 M urea. The proteins were then subjected to SDS-PAGE electrophoresis. The 53,000 mol wt two-chain Figure 8 . Activation mechanism of the plasma fibrinolytic enzyme system after oral administration of human urinary HMW-UK.
UK-type protein was found to be essentially inactive. The dissociation of the UK-UK inhibitor complex resulted in an inactive enzyme. The trace amounts of active UK, -1%, could be the result of dissociation of a different UK-UK inhibitor complex, perhaps with a2-plasmin inhibitor (32), a slow UK inhibitor, where the enzyme is still in the active form.
The oral administration of UK in human subjects produced a fibrinolytic state with resulting free plasmin (and free plasminplasmin inhibitor complexes) causing the continuous conversion of Glu-plasminogen to Lys-plasminogen (7-d group, 67% Lysform). It was recently reported that a modified form of plasminogen was found in plasma activated by UK (33). The continual presence of Lys-plasminogen in the circulation could be an important component in fibrin-thrombus resolution, since Lys-plasminogen binds better to the fibrin-thrombus and is more easily, and readily, activatable by plasminogen activators (34) (35) (36) . We now can propose a general mechanism for the effect of the oral administration of urokinase in human subjects on stimulating the biosynthesis/release of UK-type proteins, and their effect on the conversion of Glu-plasminogen to Lysplasminogen (Fig. 8) . The new plasma components, e.g., the 53,000 mol wt, UK-zymogen, and Lys-plasminogen, could play an important role in clot resolution of the fibrin-thrombus in thromboembolic diseases. The infusion of a single-chain 55,000 mol wt UK zymogen, isolated from a transformed kidney cell culture medium, into animal models, was found to induce clot lysis (37). Work is in progress on the isolation of the UK zymogen in patients with pancreatitis given oral HMW-UK and treated with Trasylol to prevent conversion of the zymogen to the enzyme by plasmin.
